A FUNCTIONAL STUDY OF NEUROPEPTIDE Y MEDIATED ATTENUATION OF VAGAL-EVOKED BRADYCARDIA :

Краткое описание

ACKNOWLEDGEMENTS
I wish to express sincere gratitude to my supervisor, Prof. Erica Potter for
invaluable guidance, assistance and advice during the course of this project. I am
indebted to the Prince of Wales Medical Research Institute, for allowing me to
undertake this research and I thank my colleagues within the institute for providing a
stimulating, enjoyable and friendly working environment.
I would also like to thank the following people; Dr. Henri Doods and
Boehringer Ingelheim Pharma for providing and allowing the use of the Y2
antagonist BIIE0246, Dr. Herbert Herzog (Garvan Institute for Medical Research)
for supplying the Y2 and Y4 receptor-knockout mice; Dr. Ray Norton (Walter &
Eliza Hall Institute for Medical Research) and Dr. Philip Mack (Peptech Pty Ltd) for
their collaboration on Y2 analog design.
To my family, I convey my sincere appreciation for their help and moral
support at all times, with special thanks to my husband Tony for his endless
encouragement throughout this project.
Lastly, I wish to thank the National Health and Medical Research Council of
Australia for supporting this work.
3
ABSTRACT
In the heart, attenuation of cardiac vagal-evoked bradycardia for a prolonged
period is observed following strong sympathetic nerve stimulation, such as exercise.
This action is attributed to the sympathetic co-transmitter, neuropeptide Y (NPY)
released together with classical transmitter noradrenaline (NAd) during stimulation
of the nerve. The prolonged inhibition of cardiac vagal activity is thought to mirror
the effects of sympathetic activation by extending the excitatory effects of NAd on
the heart.
This thesis examines the hypothesis that NPY attenuates or inhibits cardiac
vagal-evoked bradycardia by activating the Y2 receptor subtype. The aims of this
study were twofold. Firstly, to determine the receptor subtype that is responsible for
evoking this effect and secondly, to ascertain how residues within NPY interact to
induce a conformation acceptable for full inhibitory activity.
An initial series of experiments in anaesthetised rats examined the influence
that the proline residues in the N-terminal polyproline helix of NPY have on the level
and duration of evoked inhibition. This required comparison of generated inhibitory
effects by molecules with different N-terminal proline regions, including salmon PP,
a chimeric peptide PP/NPY, and N-terminal truncated peptides. Inhibitory effects
evoked by intravenous bolus injection of the individual peptides were compared to
the actions of NPY. The combined results indicated a correlation between the
presence of proline residues in the N-terminal region and potency of inhibition on
cardiac vagal activity. As proline residues were removed, the inhibitory effect
decreased suggesting that the N-terminal polyproline region was necessary for potent
vagal attenuation. Full inhibitory action could be achieved in fragments as long, or
4
longer, than NPY 3-36, whilst shorter C-terminal fragments, such as NPY 24-36,
potential products of enzyme degradation, did not evoke potent inhibition.
A second series of experiments also in anaesthetised rats examined the
structure of N-acetyl [Leu28, 31] NPY 24-36, a potent agonist of the inhibitory action
on vagal-evoked bradycardia. This shortened C-terminal analog of NPY has
therapeutic value as a drug to treat parasympathetic hyperactivity. The results show
that structural components within N-acetyl [Leu28, 31] NPY 24-36 necessary for
potent activity are (i) its amphipathicity, resulting from the helical arrangement of
hydrophilic and hydrophobic residues (ii) side chains of arginine residues 25, 33 and
35 and (iii) a stabilised -helix extending from residues 24-32. Leucine residues
initially substituted into the NPY 24-36 fragment to produce N-acetyl [Leu28, 31] NPY
24-36 resulted in an increase in potency, as did strengthening the region between
residues 28-32 by lactamisation. It is plausible therefore to suggest that the leucine
residues within N-acetyl [Leu28, 31] NPY 24-36 stabilise the analog in the same way
that the N-terminal proline region does in the whole molecule. It is likely that by
stabilising the C-terminal amphipathic portion in both NPY and N-acetyl [Leu28, 31]
NPY 24-36 the structure necessary for the correct presentation of the extension
residues is achieved.
As the NPY mediated inhibitory action on cardiac vagal activity is proposed
as Y2 receptor evoked, a specific Y2 receptor antagonist was used to test the
selectivity of N-acetyl [Leu28, 31] NPY 24-36 for this receptor. The antagonist,
BIIE0246 significantly reduced the inhibitory effect produced by N-acetyl [Leu28, 31]
NPY 24-36 supporting the proposal that N-acetyl [Leu28, 31] NPY 24-36 acted
specifically at Y2 receptors to inhibit vagal-evoked bradycardia. This antagonist also
significantly reduced the inhibitory effect on vagal activity evoked by stimulation of
5
the cardiac sympathetic nerve. Additional experiments in Y2 receptor-knockout mice
showed intravenous injection of both NPY and N-acetyl [Leu28, 31] NPY 24-36 failed
to attenuate vagal-evoked bradycardia. Resting heart rate was however increased in
these mice with the effect considered to be centrally mediated as neither NPY nor Nacetyl
[Leu28, 31] NPY 24-36 reduced resting hear rate when injected intravenously.
As the cloned form of Y2 receptor was targeted for deletion in Y2 receptor-knockout
mice, the absence of inhibitory activity on the cardiac vagus in these mice suggests
that the same form of Y2 receptor found centrally is also present at the heart. It is
therefore plausible to suggest the Y2 receptor may also produce an inhibitory action
in regions of the brain able to affect cardiac sympathetic outflow to the heart.
The conclusions reached from the pharmacological and anatomical evidence
strongly support the hypothesis that NPY released during stimulation of the
sympathetic nerve, acts via Y2 receptors on the vagus nerve, to attenuate vagalevoked
bradycardia.
6
PUBLICATIONS ARISING FROM WORK DESCRIBED IN THIS THESIS
1. Smith-White, M.A., Wallace, D. & Potter, E.K. (1998) Sympathetic-parasympathetic
interactions at the heart in the anaesthetised rat. Journal of the Autonomic Nervous System
75, 171-175
2. Smith-White, M., Moriarty, M.J & Potter, E.K. (1998) A comparison of actions of (NPY)
agonists and antagonists at NPY Y1 and Y2 receptors in anaesthetised rats. Neuropeptides
32(2), 109-118
3. Smith-White, M.A. & Potter, E.K. (1999) Structure-activity analysis of N-acetyl [Leu28, 31]
NPY 24-36: a potent neuropeptide Y Y2 receptor agonist. Neuropeptides 33(6) 526-533
4. Smith-White, M.A., Hardy, T.A., Brock, J.A. & Potter, E.K. (2001) Effects of a selective
neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral
neuroeffector junctions. British Journal of Pharmacology, 132 861 – 868.
5. Smith-White, M.A., Herzog, H. & Potter, E.K. (2002) Role of neuropeptide Y Y2 receptors
in modulation of cardiac parasympathetic neurotransmission. Regulatory Peptides, 103 105-
111
6. Smith-White, M.A., Herzog, H. & Potter, E.K. (2002) Cardiac function in neuropeptide Y Y4
receptor knockout mice. Regulatory Peptides, 110 47-54
7. Yao S, Smith-White MA, Potter EK, Norton RS, (2002). Stabilisation of the helical structure
of Y2 selective analogues of neuropeptide y by lactam bridges. Journal of Medicinal
Chemistry 45:2310-2318.
8. Smith-White, M.A., Iismaa, T & Potter, E.K. (2003) Galanin and NPY reduce cholinergic
transmission in the heart of the anaesthetised mouse. (submitted to British journal of
Pharmacology, accepted awaiting publication).
7
TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS 2
ABSTRACT 3
PUBLICATIONS 6
ABBREVIATIONS 9
CHAPTER 1 – INTRODUCTION AND LITERATURE REVIEW 10
AUTONOMIC REGULATION OF THE HEART BEAT 11
NEUROPEPTIDE Y FAMILY OF PEPTIDES 28
NEUROPEPTIDE Y MOLECULE 34
NEUROPEPTIDE Y RECEPTORS 42
Y2 RECEPTOR 54
Y2 RECEPTOR MODELLING 61
CHAPTER 2 - METHODS AND PROTOCOLS 68
CHAPTER 3 - THE RAT AND MOUSE CARDIOVASCULAR SYSTEM AS MODELS 78
FOR THE STUDY OF INHIBITION OF VAGAL-EVOKED
BRADYCARDIA
CHAPTER 4 –EXAMINING THE CONTRIBUTION THE N-TERMINAL POLYPROLINE 93
REGION WITHIN NPY HAS ON THE LEVEL OF INHIBITION OF VAGALEVOKED
BRADYCARDIA
CHAPTER 5 – STRUCTURE- ACTIVITY ANALYSIS OF 110
N-acetyl [Leu 28, 31] NPY 24-36: A POTENT INHIBITOR
OF VAGAL-EVOKED BRADYCARDIA
8
CHAPTER 6 – EFFECTS OF SELECTIVE Y2 RECEPTOR ANTAGONIST, BIIE0246 142
ON THE INHIBITION OF VAGAL-EVOKED BRADYCARDIA THAT
FOLLOWS SYMPATHETIC STIMULATION
CHAPTER 7 - EFFECTS OF NPY AND N-acetyl [Leu 28, 31] NPY 24-36 IN
NEUROPEPTIDE Y Y2 RECEPTOR KNOCKOUT MICE 153
CHAPTER 8 - EFFECTS OF Y4 RECEPTOR DELETION ON Y2 MEDIATED
INHIBITION OF VAGAL-EVOKED BRADYCARDIA 164
CHAPTER 9 - GENERAL DISCUSSION 177
REFERENCES 183
APPENDIX 240
9
Abbreviations
ACh, acetylcholine; NAd, noradrenaline, NPY, neuropeptide Y, dmnX, dorsal
motor nucleus of the vagus; nTs, nucleus of the tractus solitarius; NA, nucleus
ambiguus; SA, sinoatrial; PVN, paraventricular nucleus; AV, atrioventricular; PYY,
peptide YY; PP, pancreatic polypeptide; PYX-1 (Ac-[3-(2,6- dichlorobenzyl)Tyr27,
D-Thr32]NPY-(27-36) amide) and PYX-2 (Ac-[3-(2,6- dichlorobenzyl)Tyr27, 36,DThr32]
NPY-(27-36) amide); PP-56 (D-myo-inositol 1,2,6-triphosphate; -trinositol);
1229U91 also known as GR231118 ([2’,4],[2’,4]homodimer of Ile-Glu-Pro-Dpr-Tyr-
Arg-Leu-Arg-Tyr-CONH2); BIBP3226 ((R)-N2 –(diphenylacetyl)-N-[(4-
hydroxyphenol) methyl] argininamide);
SR120819A (1-[2-[2-(2-naphthylsulfamoyl)-3-phenylpropionamido]-3-[-4-
(dimethylaminomethyl)-c-cyclohexylmethyl] amidino]phenyl]propioyl]-
pyrrolidine(R,R)sterioisomer); CGP 71683A (trans-naphtalene-1-sulphonic acid [4-
[(4-amino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl]-amide hydrochloride);
BIIE0246, ((S)-N2-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b,e]azepin-11-yl]-
1-piperazinyl]-2-oxo-ethyl]cyclopentyl]acetyl]-N-[2-[1,2-dihydro-3,5(4H)-dioxo-
1,2-diphenyl-3-H-1,2,4-triazol-4-y]ethyl]-argininamid.

Список литературы

REFERENCE LIST
AAKERLUND L, GETHER U, FUHLENDORFF J, SCHWARTZ TW,
THASTRUP O, 1990. Y1 receptors for neuropeptide Y are coupled to
mobilization of intracellular calcium and inhibition of adenylate cyclase.
FEBS Letters 260:73-78.
ADGEY AJ, GEDDES JS, MULHOLLAND HC, KEEGAN DAJ, PANTRIDGE JF,
1968. Incidence, significance and management of early bradyarrhythmia
complicating acute myocardial infarction. Lancet 2:1097.
ADOLPH EF, 1967. The heart's pacemaker. Scientific American 216:32-37.
ADRIAN TE, FERRI GL, BACARESE-HAMILTON AJ, FUESSL HS, POLAK
JM, BLOOM SR, 1985. Human distribution and release of a putative new gut
hormone, peptide YY. Gastroenterology 89:1070-1077.
ADRIAN TE, BACARESE-HAMILTON AJ, SMITH HA, CHOHAN P,
MANOLAS KJ, BLOOM SR, 1987. Distribution and postprandial release of
porcine peptide YY. Journal of Endocrinology 113:11-14.
ALLEN JM, GJORSTRUP P, BJORKMAN JA, EK L, ABRAHAMSSON T,
BLOOM SR, 1986. Studies on cardiac distribution and function of
neuropeptide Y. Acta Physiologica Scandinavica 126:405-411.
ALLEN JM, 1990. Molecular structure of neuropeptide Y. Annals of the New York
Academy of Science 611:86-98.
184
AMMAR DA, EADIE DM, WONG DJ, MA YY, KOLAKOWSKI LF,
YANGFENG TL, THOMPSON DA, 1996. Characterization of the human
type 2 neuropeptide Y receptor gene (NPY2R) and localization to the
chromosome 4q region containing the type 1 neuropeptide Y receptor gene.
Genomics 38:392-398.
ARDELL JL, RANDALL WC, 1986. Selective vagal innervation of sinoatrial
atrioventricular nodes in canine heart. American Journal of Physiology -
Heart & Circulatory Physiology 251:H764-H773.
ARMOUR JA, RANDALL WC, 1975. Functional anatomy of canine cardiac nerves.
Acta Anatomica 91:510-528.
BACK SA, GORENSTEIN C, 1989. Histochemical visualization of neutral
endopeptidase-24.11 (enkephalinase) activity in rat brain: cellular localization
and codistribution with enkephalins in the globus pallidus. Journal of
Neuroscience 9:4439-4455.
BAKER E, HORT YJ, BALL H, SUTHERLAND GR, SHINE J, HERZOG H, 1995.
Assignment of the human neuropeptide Y gene to chromosome 7p15.1 by
nonisotopic in situ hybridization. Genomics 26:163-164.
BALASUBRAMANIAM A, RIGEL DF, CHANCE WT, STEIN M, FISCHER JE,
KING D, PLISETSKAYA EM, 1990. Salmon pancreatic polypeptide exhibits
neuropeptide Y-like activities in rats. Peptides 11:673-677.
185
BALDOCK PA, SAINSBURY A, COUZENS M, ENRIQUEZ RF, THOMAS GP,
GARDINER EM, HERZOG H, 2002. Hypothalamic Y2 receptors regulate
bone formation. Journal of Clinical Investigation 109:915-921.
BALL HJ, SHINE J, HERZOG H, 1995. Multiple promoters regulate tissue-specific
expression of the human NPY-Y1 receptor gene. J. Biol. Chem. 270:27272-
27276.
BARABAN SC, HOLLOPETER G, ERICKSON JC, SCHWARTZKROIN PA,
PALMITER RD, 1997. Knock-out mice reveal a critical antiepileptic role for
neuropeptide Y. Journal of Neuroscience 17:8927-8936.
BARD JA, WALKER MW, BRANCHEK TA, WEINSHANK RL, 1995. Cloning
and functional expression of a human Y4 subtype receptor for pancreatic
polypeptide, neuropeptide Y, and peptide YY. Journal of Biological
Chemistry 270:26762-26765.
BARDEN JA, CUTHBERTSON RM, POTTER EK, SELBIE LA, TSENG A, 1994.
Stabilized structure of the presynaptic (Y2) receptor-specific neuropeptide Y
analog N-acetyl[Leu28,Leu31]NPY(24-36). Biochimica et Biophysica Acta -
Protein Structure & Molecular Enzymology 1206:191-196.
BARDEN JA, 1995. Structure of prejunctional receptor binding analog of human
neuropeptide Y dimer ANA-NPY. Biochemical and Biophysical Research
Communications 215:264-271.
BARKER-GIBB ML, SCOTT CJ, BOUBLIK JH, CLARKE IJ, 1995. The role of
neuropeptide Y (NPY) in the control of LH secretion in the ewe with respect
186
to season, NPY receptor subtype and the site of action in the hypothalamus.
Journal of Endocrinology 147:565-579.
BARNHAM KJ, CATALFAMO F, PALLAGHY PK, HOWLETT GJ, NORTON
RS, 1999. Helical structure and self-association in a 13 residue neuropeptide
Y Y2 receptor agonist: relationship to biological activity. Biochimica et
Biophysica Acta 1435:127-137.
BARRIOS VE, SUN JL, DOUGLASS J, TOOMBS CF, 1999. Evidence of a specific
pancreatic polypeptide receptor in rat arterial smooth muscle. Peptides
20:1107-1113.
BECK-SICKINGER AG, GAIDA W, SCHNORRENBERG G, LANG R, JUNG G,
1990. Neuropeptide Y: identification of the binding site. International
Journal of Peptide & Protein Research 36:522-530.
BECK-SICKINGER AG, JUNG G, GAIDA W, KOPPEN H, SCHNORRENBERG
G, LANG R, 1990a. Structure/activity relationships of C-terminal
neuropeptide Y peptide segments and analogues composed of sequence 1-4
linked to 25-36. European Journal of Biochemistry 194:449-456.
BECK-SICKINGER AG, KOPPEN H, HOFFMANN E, GAIDA W, JUNG G, 1993.
Cyclopeptide analogs for characterization of the neuropeptide Y Y2-receptor.
Journal of Receptor Research 13:215-228.
BECK-SICKINGER AG, WIELAND HA, WITTNEBEN H, WILLIM KD,
RUDOLF K, JUNG G, 1994. Complete L-alanine scan of neuropeptide Y
187
reveals ligands binding to Y1 and Y2 receptors with distinguished
conformations. European Journal of Biochemistry 225:947-958.
BECK A, JUNG G, GAIDA W, KOPPEN H, LANG R, SCHNORRENBERG G,
1989. Highly potent and small neuropeptide Y agonist obtained by linking
NPY 1-4 via spacer to alpha-helical NPY 25-36. FEBS Letters 244:119-122.
BLASQUEZ C, JEGOU S, TRANCHAND BUNEL D, FOURNIER A, VAUDRY
H, 1992. Neuropeptide Y inhibits alpha-MSH release from rat hypothalamic
slices through a pertussis toxin-sensitive G protein. Brain Res. Mol. Brain
Res. 596:163-168.
BLEAKMAN D, COLMERS WF, FOURNIER A, MILLER RJ, 1991. Neuropeptide
Y inhibits Ca2+ influx into cultured dorsal root ganglion neurones of the rat
via a Y2 receptor. British Journal of Pharmacology 103:1781-1789.
BLEAKMAN D, HARRISON NL, COLMERS WF, MILLER RJ, 1992.
Investigations into neuropeptide Y-mediated presynaptic inhibition in
cultured hippocampal neurones of the rat. British Journal of Pharmacology
107:334-340.
BLUNDELL T J., PITTS J E, TICKLE I J, WOOD S P, and WU C-W. 1981 X-ray
analysis (1. 4 Å resolution) of avian pancreatic polypeptide: small globular
protein hormone. Proceedings of the National Academy of Sciences of the
United States of America 78, 4175-4179.
BOUBLIK JH, SCOTT NA, BROWN MR, RIVIER JE, 1989. Synthesis and
hypertensive activity of neuropeptide Y fragments and analogues with
188
modified N- or C-termini or D-substitutions. Journal of Medicinal Chemistry
32:597-601.
BRAKCH N, RIST B, BECK-SICKINGER AG, GOENAGA J, WITTEK, BURGER
E, BRUNNER HR, GROUZMANN E, 1997. Role of prohormone
convertases in pro-neuropeptide Y processing: coexpression and in vitro
kinetic investigations. Biochemistry 36:16309-16320.
BROBERGER C, JOHANSEN J, BRISMAR H, JOHANSSON C, SCHALLING M,
HOKFELT T, 1999. Changes in neuropeptide Y receptors and proopiomelanocortin
in the anorexia (anx/anx) mouse hypothalamus. Journal of
Neuroscience 19:7130-7139.
BRODDE OE, MICHEL MC, 1999. Adrenergic and muscarinic receptors in the
human heart. Pharmacological Reviews 51:651-690.
BROWN H, 1982. Electrophysiology of the sinoatrial node. Physiological Reviews
62:505-530.
BUNNETT NW, TURNER AJ, HRYSZKO J, KOBAYASHI R, WALSH JH, 1988.
Isolation of endopeptidase-24.11 (EC 3.4.24.11, "enkephalinase") from the
pig stomach. Hydrolysis of substance P, gastrin-releasing peptide 10, [Leu5]
enkephalin, and [Met5] enkephalin. Gastroenterology 95:952-957.
BURGEN ASV, TERROUX KG, 1953. On the negative inotropic effect in the cat's
auricle. Journal of Physiology-London 120:449-464.
189
BURKHOLDER T, CHAMBERS M, HOTMIRE K, WURSTER RD, MOODY S,
RANDALL WC, 1992. Gross and microscopic anatomy of the vagal
innervation of the rat heart. Anatomical Record 232:444-452.
CARRIER GO, BISHOP VS, 1972. The interaction of acetylcholine and
norepinephrine on heart rate. Journal of Pharmacology and Experimental
Therapeutics 180:31-37.
CASTAN I, VALET P, VOISIN T, QUIDEAU N, LABURTHE M, LAFONTAN M,
1992. Identification and functional studies of a specific peptide YYpreferring
receptor in dog adipocytes. Endocrinology 131:1970-1976.
CERATI D, SCHWARTZ PJ, 1991. Single cardiac vagal fibre activity, acute
myocardial ischemia, and risk for sudden death. Circulation Research
69:1389-1401.
CHEUNG DW, DUKKIPATI R, 1991. An electrophysiological study on the effect
of neuropeptide Y on sympathetic neurotransmission in guinea pig vas
deferens. Journal of Pharmacology & Experimental. Therapeutics. 257:979-
983.
CHU SS, VELDE DV, SHOBE D, BALSE P, DOUGHTY MB, 1995.
Conformational properties of the proline region of porcine neuropeptide Y by
CD and 1H-nmr spectroscopy. Biopolymers 35:583-593.
COLMERS WF, PITTMAN QJ, 1989. Presynaptic inhibition by neuropeptide Y and
baclofen in hippocamp us: insensitivity to pertussis toxin treatment. Brain
Research, Molecular Brain Research 498:99-104.
190
COLMERS WF, KLAPSTEIN GJ, FOURNIER A, ST-PIERRE S, TREHERNE KA,
1991. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in
vitro is mediated by a Y2 receptor. British Journal of Pharmacology 102:41-
44.
COOTE JH, 1984. Spinal and supraspinal reflex pathways of cardiovascular
sympathetic reflexes. Neuroscience Letters 46:243-247.
COPELAND RA, 1994. Methods for protein analysis .New York: Chapman & Hall.
COURTICE GP, KWONG TE, LUMBERS ER, POTTER EK, 1984. Excitation of
the cardiac vagus by vasopressin in mammals. Journal of Physiology
354:547-556.
COURTICE GP, 1991. Effect of neuropeptide-Y and galanin on autonomic control
of heart rate in the toad, Bufo marinus. Journal of the Autonomic Nervous
System 33:231-238.
COURTICE GP, POTTER EK, MCCLOSKEY DI, 1993. Inhibition of cardiac vagal
action by galanin but not neuropeptide Y in the brush-tailed possum
Trichosurus vulpecula. Journal of Physiology 461:379-386.
COWLEY DJ, HOFLACK JM, PELTON JT, SAUDEK V, 1992. Structure of
neuropeptide Y dimer in solution. European Journal of Biochemistry
205:1099-1106.
COX HM, CUTHBERT AW, 1990. The effects of neuropeptide Y and its fragments
upon basal and electrically stimulated ion secretion in rat jejunum mucosa.
British Journal of Pharmacology 101:247-252.
191
CRISCIONE L, RIGOLLIER P, BATZL-HARTMANN C, RUEGER H,
STRICKER K, WYSS P, BRUNNER L, WHITEBREAD S, YAMAGUCHI
Y, GERALD C, HEURICH RO, WALKER MW, CHIESI M, SCHILLING
W, HOFBAUER KG, LEVENS N, 1998. Food intake in free-feeding and
energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
Journal of Clinical Investigation 102:2136-2145.
DAHLOF C, DAHLOF P, TATEMOTO K, LUNDBERG JM, 1985. Neuropeptide Y
(NPY) reduces field stimulation-evoked release of noradrenaline and
enhances force of contraction in the rat portal vein. Naunyn-Schmiedebergs
Archives of Pharmacology 328:327-330.
DALE HH, FELDBERG W, 1934. The chemical transmission of secretory impulses
to the sweat gland of the cat. Journal of Physiology 82:121-128.
DAMPNEY RA, 1994. Functional organization of central pathways regulating the
cardiovascular system. Physiological Reviews 74:323-364.
DANHO W, TRISCARI J, VINCENT G, NAKAJIMA T, TAYLOR J, KAISER ET,
1988. Synthesis and biological evaluation of pNPY fragments. International
Journal of Peptide & Protein Research 32:496-505.
DANIELS AJ, MATTHEWS JE, SLEPETIS RJ, JANSEN M, VIVEROS OH,
TADEPALLI A, HARRINGTON W, HEYER D, LANDAVAZO A, LEBAN
JJ, ET AL, 1995. High-affinity neuropeptide Y receptor antagonists.
Proceedings of the National Academy of Science U. S. A. 92:9067-9071.
192
DARBY K, EYRE HJ, LAPSYS N, COPELAND NG, GILBERT DJ, COUZENS M,
ANTONOVA O, SUTHERLAND GR, JENKINS NA, HERZOG H, 1997.
Assignment of the Y4 receptor gene (PPYR1) to human chromosome
10q11.2 and mouse chromosome 14. Genomics 46:513-515.
DE POTTER WP, KURZAWA R, MISEREZ B, COEN EP, 1995. Evidence against
differential release of noradrenaline, neuropeptide Y, and dopamine-betahydroxylase
from adrenergic nerves in the isolated perfused sheep spleen.
Synapse 19:67-76.
DEGRADO WF, 1988. Design of peptides and proteins. Advances in Protein
Chemistry 39:51-124.
DES SENANAYAKE P, WARNER MR, BROSNIHAN KB, LEVY MN,
FERRARIO CM, 1992. Circulating neuropeptide Y in dog plasma consists of
multiple peptide fragments. Peptides 13:1165-1173.
DINGER, M.C., BADER, J.E., KOBOR, A.D., KRETZSCHMAR, A.K.,BECKSICKENGER,
A.G. 2003 Homodimerisation of neuropeptide Y receptors
investigated by fluorescence resonance energy transfer in living cells. Journal
of Biological Chemistry 10 (in-press)
DONOSO MV, SILVA M, ST-PIERRE S, HUIDOBRO-TORO JP, 1988.
Neuropeptide Y (NPY), an endogenous presynaptic modulator of adrenergic
neurotransmission in the rat vas deferens: structural and functional studies.
Peptides 9:545-553.
193
DOODS HN, KRAUSE J, 1991. Different neuropeptide Y receptor subtypes in rat
and rabbit vas deferens. European Journal of Pharmacology 204:101-103.
DOODS HN, WIELAND HA, ENGEL W, EBERLEIN W, WILLIM KD,
ENTZEROTH M, WIENEN W, RUDOLF K, 1996. BIBP 3226, the first
selective neuropeptide Y1 receptor antagonist: a review of its
pharmacological properties. [Review] [48 refs]. Regulatory Peptides 65:71-
77.
DOODS H, GAIDA W, WIELAND HA, DOLLINGER H, SCHNORRENBERG G,
ESSER F, ENGEL W, EBERLEIN W, RUDOLF K, 1999. BIIE0246: A
selective and high affinity neuropeptide YY2 receptor antagonist. European
Journal of Pharmacology 384:R3-R5.
DOUGHTY MB, HU L, 1993. The contribution of helical potential to the in vitro
receptor binding activity of a neuropeptide Y N-terminal deletion fragment.
Biopolymers 33:1195-1206.
DUMONT Y, FOURNIER A, QUIRION R, 1998. Expression and characterization
of the neuropeptide Y Y5 receptor subtype in the rat brain. Journal of
Neuroscience 18:5565-5574.
DUMONT Y, FOURNIER A, ST-PIERRE S, QUIRION R, 1993. Comparative
characterization and autoradiographic distribution of neuropeptide Y receptor
subtypes in the rat brain. Journal of Neuroscience 13:73-86.
DUMONT Y, SATOH H, CADIEUX A, TAOUDI-BENCHEKROUN M, PHENG
LH, ST-PIERRE S, FOURNIER A, QUIRION R, 1993a. Evaluation of
194
truncated neuropeptide Y analogues with modifications of the tyrosine
residue in position 1 on Y1, Y2 and Y3 receptor sub-types. European Journal
of Pharmacology 238:37-45.
DUMONT Y, CADIEUX A, DOODS H, PHENG LH, ABOUNADER R, HAMEL
E, JACQUES D, REGOLI D, QUIRION R, 2000. BIIE0246, a potent and
highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. British
Journal of Pharmacology 129:1075-1088.
EBERLEIN GA, EYSSELEIN VE, SCHAEFFER M, LAYER P, GRANDT D,
GOEBELL H, NIEBEL W, DAVIS M, LEE TD, SHIVELY JE, 1989. A new
molecular form of PYY: structural characterization of human PYY(3-36) and
PYY(1-36). Peptides 10:797-803.
EDVINSSON L, EKBLAD E, HAKANSON R, WAHLESTEDT C, 1984.
Neuropeptide Y potentiates the effect of various vasoconstrictor agents on
rabbit blood vessels. British Journal of Pharmacology 83:519-525.
EDVINSSON L, ADAMSSON M, JANSEN I, 1990. Neuropeptide Y antagonistic
properties of D-myo-inositol-1.2.6- trisphosphate in guinea pig basilar
arteries. Neuropeptides 17:99-105.
EKBLAD E, EDVINSSON L, WAHLESTEDT C, UDDMAN R, HAKANSON R,
SUNDLER F, 1984. Neuropeptide Y co-exists and co-operates with
noradrenaline in perivascular nerve fibers. Regul. Pept. 8:225-235.
EKBLAD E, SUNDLER F, 2002. Distribution of pancreatic polypeptide and peptide
YY. Peptides 23:251-261.
195
ELLIS JL, BURNSTOCK G, 1990. Neuropeptide Y neuromodulation of sympathetic
co-transmission in the guinea-pig vas deferens. British Journal of
Pharmacology 100:457-462.
ERIKSSON H, BERGLUND MM, HOLMBERG SK, KAHL U, GEHLERT DR,
LARHAMMAR D, 1998. The cloned guinea pig pancreatic polypeptide
receptor Y4 resembles more the human Y4 than does the rat Y4. Regulatory
Peptides 75-76:29-37.
EVA C, KEINANEN K, MONYER H, SEEBURG P, SPRENGEL R, 1990.
Molecular cloning of a novel G protein-coupled receptor that may belong to
the neuropeptide receptor family. FEBS Letters 271:81-84.
EVA C, OBERTO A, SPRENGEL R, GENAZZANI E, 1992. The murine NPY-1
receptor gene. Structure and delineation of tissue-specific expression. FEBS
Letters 314:285-288.
EWALD DA, STERNWEIS PC, MILLER RJ, 1988. Guanine nucleotide-binding
protein Go-induced coupling of neuropeptide Y receptors to Ca2+ channels in
sensory neurons. Proceedings of the National Academy of Science U. S. A.
85:3633-3637.
EWALD DA, PANG IH, STERNWEIS PC, MILLER RJ, 1989. Differential G
protein-mediated coupling of neurotransmitter receptors to Ca2+ channels in
rat dorsal root ganglion neurons in vitro. Neuron 2:1185-1193.
196
FEE JD, RANDALL WC, WURSTER RD, ARDELL JL, 1987. Selective ganglionic
blockade of vagal inputs to sinoatrial and/or atrioventricular regions. Journal
of Pharmacology and Experimental Therapeutics 242:1006-1012.
FLOOD JF, MORLEY JE, 1989. Dissociation of the effects of neuropeptide Y on
feeding and memory: evidence for pre- and postsynaptic mediation. Peptides
10:963-966.
FOREST M, MARTEL JC, ST-PIERRE S, QUIRION R, FOURNIER A, 1990.
Structural study of the N-terminal segment of neuropeptide tyrosine. Journal
of Medicinal Chemistry 33:1615-1619.
FORSGREN S, 1989. Neuropeptide Y-like immunoreactivity in relation to the
distribution of sympathetic nerve fibers in the heart conduction system.
Journal of Molecular & Cellular Cardiology 21:279-290.
FOUCART S, MAJEWSKI H, 1989. Inhibition of noradrenaline release by
neuropeptide Y in mouse atria does not involve inhibition of adenylate
cyclase or a pertussis toxin-susceptible G protein. Naunyn-Schmiedebergs
Archives of Pharmacology 340:658-665.
FOURNIER A, GAGNON D, QUIRION R, CADIEUX A, DUMONT Y, PHENG
LH, ST-PIERRE S, 1994. Conformational and biological studies of
neuropeptide Y analogs containing structural alterations. Molecular
Pharmacology 45:93-101.
197
FRANCO-CERECEDA A, LUNDBERG JM, DAHLOF C, 1985. Neuropeptide Y
and sympathetic control of heart contractility and coronary vascular tone.
Acta Physiologica Scandinavica 124:361-369.
FRANCO-CERECEDA A, SARIA A, LUNDBERG JM, 1989. Differential release
of calcitonin gene-related peptide and neuropeptide Y from the isolated heart
by capsaicin, ischaemia, nicotine, bradykinin and ouabain. Acta Physiologica
Scandinavica 135:173-187.
FRANCO-CERECEDA A, OWALL A, SETTERGREN G, SOLLEVI A,
LUNDBERG JM, 1990. Release of neuropeptide Y and noradrenaline from
the human heart after aortic occlusion during coronary artery surgery.
Cardiovascular Research 24:242-246.
FUHLENDORFF J, GETHER U, AAKERLUND L, LANGELAND-JOHANSEN N,
THOGERSEN H, MELBERG SG, OLSEN UB, THASTRUP O,
SCHWARTZ TW, 1990. [Leu31, Pro34]neuropeptide Y: a specific Y1
receptor agonist. Proceedings of the National Academy of Science U. S. A.
87:182-186.
FUHLENDORFF J, JOHANSEN NL, MELBERG SG, THOGERSEN H,
SCHWARTZ TW, 1990a. The antiparallel pancreatic polypeptide fold in the
binding of neuropeptide Y to Y1 and Y2 receptors. Journal of Biological
Chemistry 265:11706-11712.
FURUKAWA Y, WALLICK DW, MARTIN RJ, LEVY ML, 1990. Chronotropic
and dromotropic responses to stimulation of intracardiac sympathetic nerves
198
to sinoatrial or atrioventricular nodal regions in anaesthetised dogs.
Circulation Research 66:1391-1399.
GABRIEL M, SELLER H, 1969. Excitation of expiratory neurones adjacent to the
nucleus ambiguus by carotid sinus baroreceptor and trigeminal afferents.
Pflugers Archiv - European Journal of Physiology 313:1-10.
GANDEVIA SC, MCCLOSKEY DI, POTTER EK, 1978. Inhibition of baroreceptor
and chemoreceptor reflexes on heart rate by afferents from the lungs. Journal
of Physiology 276:369-381.
GANGULY PK, 2000. Neuropeptide Y receptors: Future therapeutic target in
congestive heart failure. Journal of Health Science 46 (6) 430-433
GEFFEN LB, LIVETT BG, 1971. Synaptic vesicles in sympathetic neurons.
Physiological Reviews 51:98-157.
GEHLERT DR, BEAVERS LS, JOHNSON D, GACKENHEIMER SL, SCHOBER
DA, GADSKI RA, 1996. Expressional cloning of a human brain
neuropeptide Y Y2 receptor. Molecular Pharmacology 49:224-228.
GEHLERT DR, SCHOBER DA, BEAVERS L, GADSKI R, HOFFMAN JA,
SMILEY DL, CHANCE RE, LUNDELL I, LARHAMMAR D, 1996a.
Characterization of the peptide binding requirements for the cloned human
pancreatic polypeptide-preferring receptor. Molecular Pharmacology
50:112-118.
GEHLERT DR, SCHOBER DA, GACKENHEIMER SL, BEAVERS L, GADSKI
R, LUNDELL I, LARHAMMAR D, 1997. [I-125]Leu(31), Pro(34)-PYY is a
199
high affinity radioligand for rat PP1/Y4 and Y1 receptors - evidence for
heterogeneity in pancreatic polypeptide receptors. Peptides 18:397-401.
GERALD C, WALKER MW, VAYSSE PJ, HE C, BRANCHEK TA,
WEINSHANK RL, 1995. Expression cloning and pharmacological
characterization of a human hippocampal neuropeptide Y/peptide YY Y2
receptor subtype. Journal of Biological Chemistry 270:26758-26761.
GERALD C, WALKER MW, CRISCIONE L, GUSTAFSON EL, BATZLHARTMANN
C, SMITH, KE, VAYSSE P, DURKIN MM, LAZ TM,
LINEMEYER DL, SCHAFFHAUSER AO, WHITEBREAD S, HOFBAUER
KG, TABER RI, BRANCHEK TA, WEINSHANK RL, 1996. A receptor
subtype involved in neuropeptide-Y-induced food intake Nature 382:168-
171.
GIULIANI S, MAGGI CA, MELI A, 1989. Prejunctional modulatory action of
neuropeptide Y on peripheral terminals of capsaicin-sensitive sensory nerves.
British Journal of Pharmacology 98:407-412.
GLOVER I, BARLOW DJ, PITTS J E, WOOD S P, BLUNDELL T J., TATEMOTO
K, KIMMEL J, WOLLMER A, STRAUSSBURGER W, ZHANG YS, 1985.
Conformational studies on the pancreatic polypeptide hormone family.
European Journal of Biochemistry 142:379-385.
GRANDT D, SIEWERT J, SIEBURG B, AL TAI O, SCHIMICZEK M, GOEBELL
H, LAYER P, EYSSELEIN VE, REEVE JR, JR., MULLER MK, 1995.
Peptide YY inhibits exocrine pancreatic secretion in isolated perfused rat
pancreas by Y1 receptors. Pancreas 10:180-186.
200
GREGOR P, FENG Y, DECARR LB, CORNFIELD LJ, MCCALEB ML, 1996.
Molecular characterization of a second mouse pancreatic polypeptide
receptor and its inactivated human homologue. Journal of Biological
Chemistry 271:27776-27781.
GREGOR P, MILLHAM ML, FENG Y, DECARR LB, MCCALEB ML,
CORNFIELD LJ, 1996a. Cloning and characterization of a novel receptor to
pancreatic polypeptide, a member of the neuropeptide Y receptor family.
FEBS Letters 381:58-62.
GRODNER AS, LAHRTZ HG, POOL PE, BRAUNWALD PH, 1970.
Neurotransmitter control of sinoatrial pacemaker frequency in isolated rat
atria and in intact rabbits. Circulation Research 27:867-873.
GROUZMANN E, BUCLIN T, MARTIRE M, CANNIZZARO C, DORNER B,
RAZANAME A, MUTTER M, 1997. Characterization of a selective
antagonist of neuropeptide Y at the Y2 receptor. Synthesis and
pharmacological evaluation of a Y2 antagonist Journal of Biological
Chemistry 272:7699-7706.
GROUZMAN E, MEYER C, BURKI E, BRUNNER H, 2001. Neuropeptide Y Y2
receptor signaling mechanisms in the human glioblastoma cell line LN319.
Peptides 22:379-386.
GRUNDEMAR L, WIDMARK E, WALDECK B, HAKANSON R, 1988.
Neuropeptide Y: prejunctional inhibition of vagally induced contractions in
the guinea pig trachea. Regulatory Peptides 23:309-313.
201
GRUNDEMAR L, GRUNDSTROM N, JOHANSSON IG, ANDERSSON RG,
HAKANSON R, 1990. Suppression by neuropeptide Y of capsaicin-sensitive
sensory nerve-mediated contraction in guinea-pig airways. British Journal of
Pharmacology 99:473-476.
GRUNDEMAR L, HAKANSON R, 1990. Effects of various neuropeptide Y/peptide
YY fragments on electrically-evoked contractions of the rat vas deferens.
British Journal of Pharmacology 100:190-192.
GRUNDEMAR L, JONAS SE, MORNER N, HOGESTATT ED, WAHLESTEDT
C, HAKANSON R, 1992. Characterization of vascular neuropeptide Y
receptors. British Journal of Pharmacology 105:45-50.
GRUNDEMAR L, WAHLESTEDT C, WANG ZY, 1993. Neuropeptide Y
suppresses the neurogenic inflammatory response in the rabbit eye; mode of
action. Regulatory Peptides 43:57-64.
GU J, POLAK JM, ADRIAN TE, ALLEN JM, TATEMOTO K, BLOOM SR, 1983.
Neuropeptide tyrosine (NPY)--a major cardiac neuropeptide. Lancet 1:1008-
1010.
GU J, POLAK JM, ALLEN JM, HUANG WM, SHEPPARD MN, TATEMOTO K,
BLOOM SR, 1984. High concentrations of a novel peptide, neuropeptide Y,
in the innervation of mouse and rat heart. Journal of Histochemistry &
Cytochemistry 32:467-472.
GUSTAFSON EL, SMITH KE, DURKIN MM, WALKER MW, GERALD C,
WEINSHANK R, BRANCHEK TA, NEUROPEPTIDE, HYBRIDIZATION
202
IS, RAT, HIPPOCAMPUS, HYPOTHALAMUS, TRIGEMINAL G, 1997.
Distribution of neuropptide Y Y2 receptor mRNA in rat central nervous
system. Brain Research, Molecular Brain Research 46:223-235.
HAASS M, CHENG B, RICHARDT G, LANG RE, SCHOMIG A, 1989.
Characterization and presynaptic modulation of stimulation- evoked
exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig
heart. Naunyn-Schmiedebergs Archives of Pharmacology 339:71-78.
HAASS M, HOCK M, RICHARDT G, SCHOMIG A, 1989a. Neuropeptide Y
differentiates between exocytotic and nonexocytotic noradrenaline release in
guinea-pig heart. Naunyn-Schmiedebergs Archives of Pharmacology
340:509-515.
HASSALL CJ, BURNSTOCK G, 1987. Immunocytochemical localisation of
neuropeptide Y and 5- hydroxytryptamine in a subpopulation of aminehandling
intracardiac neurones that do not contain dopamine betahydroxylase
in tissue culture. Brain Research, Molecular Brain Research
422:74-82.
HAYMET BT, MCCLOSKEY DI, 1975. Baroreceptor and chemoreceptor influences
on heart rate during the respiratory cycle in the dog. Journal of Physiology
245:699-712.
HEGDE SS, BONHAUS DW, STANLEY W, EGLEN RM, MOY TM, LOEB M,
SHETTY SG, DESOUZA A, KRSTENANSKY J, 1995. Pharmacological
evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y203
Y1 receptor antagonist. Journal of Pharmacology and Experimental
Therapeutics 275:1261-1266.
HENRY JL, CALARESU FR, 1972. Distribution of cardioacceleratory sites in
intermediolateral nucleus of the cat. American Journal of Physiology
222:700-704.
HERNANDEZ EJ, WHITCOMB DC, VIGNA SR, TAYLOR IL, 1994. Saturable
binding of circulating peptide YY in the dorsal vagal complex of rats.
American Journal of Physiology 266:t-6.
HERZOG H, HORT YJ, BALL HJ, HAYES G, SHINE J, SELBIE LA, 1992.
Cloned human neuropeptide Y receptor couples to two different second
messenger systems. Proc. Natl. Acad. Sci. U. S. A. 89:5794-5798.
HERZOG H, BAUMGARTNER M, VIVERO C, SELBIE LA, AUER B, SHINE J,
1993. Genomic organization, localization, and allelic differences in the gene
for the human neuropeptide Y Y1 receptor. Journal of Biological Chemistry
268:6703-6707.
HERZOG H, DARBY K, BALL H, HORT Y, BECKSICKINGER A, SHINE J,
1997. Overlapping gene structure of the human neuropeptide Y receptor
subtypes Y1 and Y5 suggests coordinated transcriptional regulation.
Genomics 41:315-319.
HIGGINS CB, VATNER SF, BRAUNWALD E, 1973. Parasympathetic control of
the heart. Pharmacological Reviews 25:119-155.
204
HIGUCHI H, YANG HY, SABOL SL, 1988. Rat neuropeptide Y precursor gene
expression. mRNA structure, tissue distribution, and regulation by
glucocorticoids, cyclic AMP, and phorbol ester. Journal of Biological
Chemistry 263:6288-6295.
HORT Y, BAKER E, SUTHERLAND GR, SHINE J, HERZOG H, 1995. Gene
duplication of the human peptide YY gene (PYY) generated the pancreatic
polypeptide gene (PPY) on chromosome 17q21.1. Genomics 26:77-83.
HU Y, BLOOMQUIST BT, CORNFIELD LJ, DECARR LB, FLORES-RIVEROS
JR, FRIEDMAN L, JIANG P, LEWIS-HIGGINS L, SADLOWSKI Y,
SCHAEFER J, VELAZQUEZ N, MCCALEB ML, 1996. Identification of a
novel hypothalamic neuropeptide Y receptor associated with feeding
behavior. Journal of Biological Chemistry 271:26315-26319.
HULTING J, SOLLEVI A, ULLMAN B, FRANCO-CERECEDA A, LUNDBERG
JM, 1990. Plasma neuropeptide Y on admission to a coronary care unit:
raised levels in patients with left heart failure. Cardiovascular Research
24:102-108.
JACOBOWITZ D, COOPER T, BARNER HB, 1967. Histochemical and chemical
studies of the localisation of adrenergic and cholinergic nerves in normal and
dennervated cat hearts. Circulation Research 20:289-298.
JALIFE J, MICHAELS DC, 1994. Neural control of sinoatrial pacemaker activity.In:
Levy MN, Schwartz PJ, eds. Vagal Control of the Heart: Experimental Basis
and Clinical Implications. New York: Futura, 173-206.
205
JANES RD, BRANDYS JC, HOPKINS DA, JOHNSTONE DE, MURPHY DA,
ARMOUR JA, 1986. Anatomy of human extrinsic cardiac nerves and
ganglia. American Journal of Cardiology 57:299-309.
JÖNSSON-RYLANDER AC, NORDLANDER M, SVINDLAND A, IIEBEKK A.
2003. Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem
human heart. Peptides 24, 255-262
JORGENSEN JC, FUHLENDORFF J, SCHWARTZ TW, 1990. Structure-function
studies on neuropeptide Y and pancreatic polypeptide--evidence for two PPfold
receptors in vas deferens. European Journal of Pharmacology 186:105-
114.
JUNG G, BECK-SICKINGER AG, DURR H, GAIDA W, SCHNORRENBERG G,
1991. Alpha-helical small molecular size analogues of neuropeptide Y:
structure-activity relationships. Biopolymers 31:613-619.
KAIJSER L, PERNOW J, BERGLUND B, LUNDBERG JM, 1990. Neuropeptide Y
is released together with noradrenaline from the human heart during exercise
and hypoxia. Clinical Physiology 10:179-188.
KAIJSER L, PERNOW J, BERGLUND B, GRUBBSTROM J, LUNDBERG JM,
1994. Neuropeptide Y release from human heart is enhanced during
prolonged exercise in hypoxia. Journal of Applied Physiology 76:1346-1349.
KAISER ET, KEZDY FJ, 1984. Amphiphilic secondary structure: design of peptide
hormones. [Review] [32 refs]. Science 223:249-255.
206
KALIA M, MESULAM MM, 1980. Brain stem projections of sensory and motor
components of the vagus complex in the cat: II. Laryngeal, tracheobronchial,
pulmonary, cardiac, and gastrointestinal branches. Journal of Comparative
Neurology 193:467-508.
KATONA PG, POITRAS JW, BARNETT GO, TERRY BS, 1970. Cardiac vagal
efferent activity and heart period in the carotid sinus reflex. American
Journal of Physiology 218:1030-1037.
KENNEDY B, SHEN GH, ZIEGLER MG, 1997. Neuropeptide Y-mediated pressor
responses following high frequency stimulation of the rat sympathetic
nervous system. Journal of Pharmacology and Experimental Therapeutics
281:291-296.
KILBORN MJ, POTTER EK, MCCLOSKEY DI, 1985. Neuromodulation of the
cardiac vagus: comparison of neuropeptide Y and related peptides.
Regulatory Peptides 12:155-161.
KING PJ, WIDDOWSON PS, DOODS HN, WILLIAMS G, 1999. Regulation of
neuropeptide Y release by neuropeptide Y receptor ligands and calcium
channel antagonists in hypothalamic slices. Journal of Neurochemistry
73:641-646.
KING PJ, WILLIAMS G, DOODS H, WIDDOWSON PS, 2000. Effect of a
selective neuropeptide Y Y2 receptor antagonist, BIIE0246 on neuropeptide
Y release. European Journal of Pharmacology 396:R1-R3.
207
KOO-LOEB JH, PEDERSEN C, GIRDLER SS, 1998. Blunted cardiovascular and
catecholamine stress reactivity in women with bulimia nervosa. Psychiatry
Research 80:13-27.
KORNER PI, 1978. Role of the autonomic nervous system in reflex cardiovascular
control. .In: Yu F, P.N., Goodwin JF, eds. Progress in Cardiology.
Philadelphia: Lea and Febiger, 55-101.
KRAUSE J, EVA C, SEEBURG PH, SPRENGEL R, 1992. Neuropeptide Y1
subtype pharmacology of a recombinantly expressed neuropeptide receptor.
Molecular Pharmacology 41:817-821.
LACROIX JS, ULMAN LG, POTTER EK, 1994. Modulation by neuropeptide Y of
parasympathetic nerve-evoked nasal vasodilatation via Y2 prejunctional
receptor. British Journal of Pharmacology 113:479-484.
LARHAMMAR D, BLOMQVIST AG, YEE F, JAZIN E, YOO H, WAHLESTED
C, 1992. Cloning and functional expression of a human neuropeptide
Y/peptide YY receptor of the Y1 type. Journal of Biological Chemistry
267:10935-10938.
LARHAMMAR D, BLOMQVIST AG, SODERBERG C, 1993. Evolution of
neuropeptide Y and its related peptides. [Review] [86 refs]. Comparative
Biochemistry & Physiology - C: Comparative Pharmacology & Toxicology
106:743-752.
LARHAMMAR D, 1996. Evolution of neuropeptide Y, peptide YY and pancreatic
polypeptide [Review]. Regulatory Peptides 62:1-11.
208
LARHAMMAR D, 1996a. Structural diversity of receptors for neuropeptide Y,
peptide YY and pancreatic polypeptide. [Review] [64 refs]. Regulatory
Peptides 65:165-174.
LARHAMMAR D, SODERBERG C, LUNDELL I, 1998. Evolution of the
neuropeptide Y family and its receptors. [Review] Annals of the New York
Academy of Science 839:35-40.
LARSEN PJ, JUKES KE, CHOWDREY HS, LIGHTMAN SL, JESSOP DS, 1994.
Neuropeptide-Y potentiates the secretion of vasopressin from the
neurointermediate lobe of the rat pituitary gland. Endocrinology 134:1635-
1639.
LARSEN PJ, KRISTENSEN P, 1997. The neuropeptide Y (Y4) receptor is highly
expressed in neurones of the rat dorsal vagal complex. Brain Research,
Molecular Brain Research. 48:1-6.
LEDSOME JR, LINDEN RJ, 1964. A reflex increase in heart rate from distension of
the pulmonary vein-atrial junction. Journal of Physiology-London 170:456-
473.
LEIBOWITZ SF, XUEREB M, KIM T, 1992. Blockade of natural and neuropeptide
Y-induced carbohydrate feeding by a receptor antagonist PYX-2.
Neuroreport 3:1023-1026.
LEMOS VS, TAKEDA K, 1995. Neuropeptide Y2-type receptor-mediated activation
of large- conductance Ca(2+)-sensitive K+ channels in a human
209
neuroblastoma cell line. Pflugers Archiv - European Journal of Physiology
430:534-540.
LEVY MN, ZIESKE H, 1969. Autonomic control of cardiac pacemaker activity and
atrioventricular transmission. Journal of Applied Physiology 27:465-470.
LEVY MN, BLATTBERG MS, 1976. Effect of vagal stimulation on the overflow of
norepinephrine into the coronary sinus during cardiac sympathetic nerve
stimulation in the dog. Circulation Research 38:84-85.
LEVY MN, MARTIN PJ, 1979. Neural control of the heart.In: Berne RM, ed.
Handbook of Physiology: The Cardiovascular System. Bethesda, Maryland:
American Physiological Society, 581-620.
LEVY MN, YANG T, WALLICK DW, 1993. Assessment of beat-by-beat control of
heart rate by the autonomic nervous system: Molecular biology technics are
necessary, but not sufficient. Journal Of Cardiovascular Electrophysiology
4:183-193.
LEW MJ, MURPHY R, ANGUS JA, 1996. Synthesis and characterisation of a
selective peptide antagonist of neuropeptide Y vascular postsynaptic
receptors British Journal of Pharmacology 117:1768-1772.
LEWIS CJ, EVANS RJ, NEILD TO, 1999. Inhibition of vasoconstriction and Ca2+
currents mediated by neuropeptide Y Y2 receptors. Journal of Smooth Muscle
Research 35:147-156.
210
LIDDELL E.G.T AND SHERRINGTON C., 1929. In: Liddell E.G.T and
Sherrington C., ed. Mammalian Physiology, A course of practical exercises.
London: Clarendon Press, p 38-47
LOEWY AD, BURTON H, 1978. Anatomical aspects of central nervous
cardiovascular regulation. Journal of Comparative Neurology 181:421-450.
LOEWY AD, WALLACH JH, MCKELLAR S, 1981. Efferent connections of the
ventral medulla oblongata in the rat. Brain Research, Molecular Brain
Research. 228:63-80.
LOFFELHOLZ K, MUSCHOLL E, 1969. A muscarinic inhibition of the
noradrenaline release evoked by postganglionic sympathetic nerve
stimulation. Naunyn-Schmiedebergs Archiv fur Pharmakologie 265:1-15.
LOFFELHOLZ K, PAPPANO AJ, 1985. The parasympathetic neuroeffector junction
of the heart. Pharmacological Reviews 37:1-24.
LOUIE DS, WILLIAMS JA, OWYANG C, 1985. Action of pancreatic polypeptide
on rat pancreatic secretion: in vivo and in vitro. American Journal of
Physiology 249:t-95.
LUMBERS ER, MCCLOSKEY DI, POTTER EK, 1979. Inhibition by angiotensin II
of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog.
Journal of Physiology 294:69-80.
LUNDBERG JM, TERENIUS L, HOKFELT T, MARTLING CR, TATEMOTO K,
MUTT V, POLAK J, BLOOM S, GOLDSTEIN M, 1982. Neuropeptide Y
(NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects
211
of NPY on sympathetic function. Acta Physiologica Scandinavica 116:477-
480.
LUNDBERG JM, TERENIUS L, HOKFELT T, GOLDSTEIN M, 1983. High levels
of neuropeptide Y in peripheral noradrenergic neurons in various mammals
including man. Neuroscience Letters 42:167-172.
LUNDBERG JM, STJARNE L, 1984. Neuropeptide Y (NPY) depresses the
secretion of 3H-noradrenaline and the contractile response evoked by field
stimulation, in rat vas deferens. Acta Physiologica Scandinavica 120:477-
479.
LUNDBERG JM, HUA XY, FRANCO-CERECEDA A, 1984a. Effects of
neuropeptide Y (NPY) on mechanical activity and neurotransmission in the
heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiologica
Scandinavica 121:325-332.
LUNDBERG JM, MARTINSSON A, HEMSEN A, THEODORSSON-NORHEIM
E, SVEDENHAG J, EKBLOM B, HJEMDAHL P, 1985. Co-release of
neuropeptide Y and catecholamines during physical exercise in man.
Biochemica et Biophysica Research Communications 133:30-36.
LUNDBERG JM, PERNOW J, TATEMOTO K, DAHLOF C, 1985a. Pre- and
postjunctional effects of NPY on sympathetic control of rat femoral artery.
Acta Physiologica Scandinavica 123:511-513.
212
LUNDBERG JM, TORSSELL L, SOLLEVI A, PERNOW J, THEODORSSON
NORHEIM E, ANGGARD A, HAMBERGER B, 1985b. Neuropeptide Y
and sympathetic vascular control in man. Regulatory Peptides 13:41-52.
LUNDBERG JM, HEMSEN A, LARSSON O, RUDEHILL A, SARIA A,
FREDHOLM BB, 1988. Neuropeptide Y receptor in pig spleen: binding
characteristics, reduction of cyclic AMP formation and calcium antagonist
inhibition of vasoconstriction. European Journal of Pharmacology 145:21-
29.
LUNDELL I, BLOMQVIST AG, BERGLUND MM, SCHOBER DA, JOHNSON
D, STATNICK MA, GADSKI RA, GEHLERT DR, LARHAMMAR D,
1995. Cloning of a human receptor of the NPY receptor family with high
affinity for pancreatic polypeptide and peptide YY. Journal of Biological
Chemistry 270:29123-29128.
LUNDELL I, STATNICK MA, JOHNSON D, SCHOBER DA, STARBACK P,
GEHLERT DR, LARHAMMAR D, 1996. The cloned rat pancreatic
polypeptide receptor exhibits profound differences to the orthologous
receptor. Proceedings of the National Academy of Science U. S. A. 93:5111-
5115.
LUTZ CM, FRANKEL WN, RICHARDS JE, THOMPSON DA, 1997.
Neuropeptide Y receptor genes on human chromosome 4q31-q32 map to
conserved linkage groups on mouse chromosomes 3 and 8 [published erratum
appears in Genomics 1997 Sep 1;44(2):251-2]. Genomics 41:498-500.
213
LUTZ CM, RICHARDS JE, SCOTT KL, SINHA S, YANG-FENG TL, FRANKEL
WN, THOMPSON DA, 1997a. Neuropeptide Y receptor genes mapped in
human and mouse: receptors with high affinity for pancreatic polypeptide are
not clustered with receptors specific for neuropeptide Y and peptide YY.
Genomics 46:287-290.
LYU PC, LIFF MI, MARKY LA, KALLENBACH NR, 1998. Side chain
contributions to the stability of alpha-helical structure in peptides. Science
250:669-673.
MACKERELL AD, JR., HEMSEN A, LACROIX JS, LUNDBERG JM, 1989.
Analysis of structure-function relationships of neuropeptide Y using
molecular dynamics simulations and pharmacological activity and binding
measurements. Regulatory Peptides 25:295-313.
MAHNS DA, LACROIX JS, POTTER EK, 1998. Inhibition of vagal vasodilatation
by a selective neuropeptide Y Y2 receptor agonist in the bronchial circulation
of anaesthetised dogs. Journal of the Autonomic Nervous System 73:80-85.
MAHNS DA, REVINGTON ML, RUNCIE MJ, MCCLOSKEY DI, POTTER EK,
1998a. Inhibition of sympathetic cholinergic vasodilatation by a selective
NPY Y2 receptor agonist in the gracilis muscle of anaesthetised dogs. Journal
of the Autonomic Nervous System 68:14-20.
MAHNS DA, KELLY C, MCCLOSKEY DI, POTTER EK, 1999. NPY Y2 receptor
agonist, N-acetyl [Leu28,Leu31]NPY24-36, reduces renal vasoconstrictor
activity in anaesthetised dogs. Journal of the Autonomic Nervous System
78:10-17.
214
MAISEL AS, SCOTT NA, MOTULSKY HJ, MICHEL MC, BOUBLIK JH,
RIVIER JE, ZIEGLER M, ALLEN RS, BROWN MR, 1989. Elevation of
plasma neuropeptide Y levels in congestive heart failure. American Journal
of Medicine 86:43-48.
MALMSTROM RE, 1997. Neuropeptide Y Y-1 receptor mechanisms in sympathetic
vascular control. Acta Physiologica Scandinavica 160:636):4-55.
MALMSTROM RE, LUNDBERG JM, 1996. Effects of the neuropeptide YY1
receptor antagonist SR 120107A on sympathetic vascular control in pigs in
vivo. Naunyn-Schmiedebergs Archives of Pharmacology 354:633-642.
MALMSTROM RE, 2001. Vascular pharmacology of BIIE0246, the first selective
non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo. British Journal
of Pharmacology 133:1073-1080.
MALMSTROM RE, LUNDBERG JN, WEITZBERG E, 2002. Effects of the
neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter
release in the pig in vivo. Naunyn-Schmiedebergs Archiv fur Pharmakologie
365:106-111.
MARKS NJ, SHAW C, HALTON DW, THIM L, 1993. The primary structure of
pancreatic polypeptide from a primitive insectivorous mammal, the European
hedgehog (Erinaceous europaeus). Regulatory Peptides 47:179-185.
MATRAN R, MARTLING CR, LUNDBERG JM, 1989. Inhibition of cholinergic
and non-adrenergic, non-cholinergic bronchoconstriction in the guinea pig
215
mediated by neuropeptide Y and alpha 2-adrenoceptors and opiate receptors.
European Journal of Pharmacology 163:15-23.
MATSUMOTO M, NOMURA T, MOMOSE K, IKEDA Y, KONDOU Y, AKIHO
H, TOGAMI J, KIMURA Y, OKADA M, YAMAGUCHI T, 1996.
Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate
species. Journal of Biological Chemistry 271:27217-27220.
MCAULEY MA, WESTFALL TC, 1992. Possible location and function of
neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. Journal
of Pharmacology and Experimental Therapeutics 261:863-868.
MCCREA K, WISIALOWSKI T, CABRELE C, CHURCH B, BECK-SICKINGER
A, KRAEGEN E, HERZOG H, 2000. 2-36[K4,RYYSA(19-23)]PP a novel
Y5-receptor preferring ligand with strong stimulatory effect on food intake.
Regulatory Peptides 87:47-58.
MCDERMOTT BJ, MILLAR BC, PIPER HM, 1993. Cardiovascular effects of
neuropeptide Y: receptor interactions and cellular mechanisms. [Review]
[173 refs]. Cardiovascular Research 27:893-905.
MEDEIROS MDS, TURNER AJ, 1996. Metabolism and functions of neuropeptide
Y. Neurochemical Research 21:1125-1132.
MICHEL MC, 1991. Receptors for neuropeptide Y: multiple subtypes and multiple
second messengers. Trends in Pharmacological Sciences 12:389-394.
216
MICHEL MC, HANFT G, GROSS G, 1994. Functional studies on a1-adrenoceptor
subtype mediating inotropic effects in rat ventricles. British Journal of
Pharmacology 35:539-546.
MICHEL MC, RASCHER W, 1995. Neuropeptide Y: a possible role in
hypertension?. [Review] [130 refs]. Journal of Hypertension 13:385-395.
MICHEL MC, BECK-SICKINGER A, COX H, DOODS HN, HERZOG H,
LARHAMMAR D, QUIRION R, SCHWARTZ T, WESTFALL T, 1998.
XVI. International Union of Pharmacology recommendations for the
nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide
receptors. [Review] [79 refs]. Pharmacological Reviews 50:143-150.
MIHARA S, SHIGERI Y, FUJIMOTO M, 1989. Neuropeptide Y-induced
intracellular Ca2+ increases in vascular smooth muscle cells. FEBS Letters
259:79-82.
MIKKELSEN JD, LAENKHOLM AV, BECK B, SVENDSEN JH, CLAUSEN PP,
1990. Neuropeptide Y is found in nerve fibres in the human myocardium as
an amidated molecule. Acta Physiologica Scandavica 138:583-584.
MILLAR BC, WEIS T, PIPER HM, WEBER M, BORCHARD U, MCDERMOTT
BJ, BALASUBRAMANIAM A, 1991. Positive and negative contractile
effects of neuropeptide Y on ventricular cardiomyocytes. American Journal
of Physiology 261:Pt 2):H1727-33.
MILLER ME, CHRISTENSEN GC, EVANS HE, 1964. Anatomy of the
dog.Philadephia: Saunders, 544-574.
217
MINTH CD, BLOOM SR, POLAK JM, DIXON JE, 1984. Cloning, characterization,
and DNA sequence of a human cDNA encoding neuropeptide tyrosine.
Proceedings of the National Academy of Science U. S. A. 81:4577-4581.
MORIARTY M, POTTER EK, MCCLOSKEY DI, 1992. Inhibition of arterial
baroreceptor and chemoreceptor reflex responses by neuropeptide Y in
anaesthetised dogs. Journal of the Autonomic Nervous System 39:169-179.
MORRIS MJ, RUSSELL AE, KAPOOR V, CAIN MD, ELLIOTT JM, WEST MJ,
WING LM, CHALMERS JP, 1986. Increases in plasma neuropeptide Y
concentrations during sympathetic activation in man. Journal of the
Autonomic Nervous System 17:143-149.
MOTULSKY HJ, MICHEL MC, 1988. Neuropeptide Y mobilizes Ca2+ and inhibits
adenylate cyclase in human erythroleukemia cells. American Journal of
Physiology 255:Pt 1):E880-5.
MULLINS DE, GUZZI M, XIA L, PARKER EM, 2000. Pharmacological
characterization of the cloned neuropeptide Y y(6) receptor. European
Journal of Pharmacology 395:87-93.
NAKAMURA M, SAKANAKA C, AOKI Y, OGASAWARA H, TSUJI T,
KODAMA H, MATSUMOTO T, SHIMIZU T, NOMA M, 1995.
Identification of two isoforms of mouse neuropeptide Y-Y1 receptor
generated by alternative splicing. Isolation, genomic structure, and functional
expression of the receptors. Journal of Biological Chemistry 270:30102-
30110.
218
NAKAMURA M, AOKI Y, HIRANO D, 1996. Cloning and functional expression of
a cDNA encoding a mouse type 2 neuropeptide Y receptor. Biochimica et
Biophysica Acta 1284:134-137.
NAKAMURA M, YOKOYAMA M, WATANABE H, MATSUMOTO T, 1997.
Molecular cloning, organization and localization of the gene for the mouse
neuropeptide Y-Y5 receptor. Biochimica Biophysica Acta 1328:83-89.
NAVEILHAN P, HASSANI H, CANALS JM, EKSTRAND AJ, LAREFALK A,
CHHAJLANI V, ARENAS E, GEDDA K, SVENSSON L, THOREN P,
ERNFORS P, 1999. Normal feeding behaviour, body weight and leptin
response require the neuropeptide YY2 receptor. Nature Medicine 5:1188-
1193.
NEILD TO, KOTECHA N, 1990. Actions of neuropeptide Y on arterioles of the
guinea-pig small intestine are not mediated by smooth muscle depolarization.
Journal of the Autonomic Nervous System 30:29-35.
NGUYEN TD, WOLFE MS, HEINTZ GG, WHITCOMB DC, TAYLOR IL, 1992.
High affinity binding proteins for pancreatic polypeptide on rat liver
membranes. Journal of Biological Chemistry 267:9416-9421.
NOBLE D, 1979. The initiation of the heartbeat.Oxford: Clarendon Press, 109-110.
NORDMANN A, BLOMMERS MJJ, FRETZ H, ARVINTE T, DRAKE AF, 1999.
Aspects of the molecular structure and dynamics of neuropeptide Y.
European Journal of Biochemistry 261:216-226.
219
NOSAKA S, YAMAMOTO T, YASUNAGA K, 1979. Localization of vagal
cardioinhibitory preganglionic neurons with rat brain stem. Journal of
Comparative Neurology 186:79-92.
NOSAKA S, NAKASE N, MURATA K, 1989. Somatosensory and hypothalamic
inhibitions of baroreflex vagal bradycardia in rats. Pflugers Archiv -
European Journal of Physiology 413:656-666.
PACKER M, 1992. Pathophysiology of chronic heart failure. Lancet 340:88-92.
PALMITER RD, ERICKSON JC, HOLLOPETER G, BARABAN SC, SCHWARTZ
MW, 1998. Life without neuropeptide Y. Recent Progress in Hormone
Research 53:163-99.:163-199.
PAQUET L, MASSIE B, MAINS RE, 1996. Proneuropeptide Y processing in large
dense-core vesicles: manipulation of prohormone convertase expression in
sympathetic neurons using adenoviruses. Journal of Neuroscience 16:964-
973.
PARDINI BJ, LUND DD, SCHMID PG, 1989. Organization of the sympathetic
postganglionic innervation of the rat heart. Journal of the Autonomic Nervous
System 28:193-201.
PARDINI BJ, LUND DD, PUK DE, 1992. Sites at which neuropeptide Y modulates
parasympathetic control of heart rate in guinea pigs and rats. Journal of the
Autonomic Nervous System. 38:139-145.
PARKER EM, BABIJ CK, BALASUBRAMANIAM A, BURRIER RE, GUZZI M,
HAMUD F, MUKHOPADHYAY G, RUDINSKI MS, TAO Z, TICE M, XIA
220
L, MULLINS DE, SALISBURY BG, 1998. GR231118 (1229U91) and other
analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y-
1 receptor antagonists and neuropeptide Y Y-4 receptor agonists. European
Journal of Pharmacology 349:97-105.
PARKER EM, BALASUBRAMANIAM A, GUZZI M, MULLINS DE,
SALISBURY BG, SHERIFF S, WITTEN MB, HWA JJ, 2000. [D-Trp(34)]
neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist
with dramatic effects on food intake. Peptides 21:393-399.
PARKER P, CELLER BG, POTTER EK, MCCLOSKEY DI, 1984. Vagal
stimulation and cardiac slowing. Journal of the Autonomic Nervous System
11:226-231.
PARKER RM, HERZOG H, 1999. Regional distribution of Y-receptor subtype
mRNAs in rat brain. European Journal of Neuroscience 11:1431-1448.
PEREZ-GOMEZ F, DE DIOS RM, REY J, AGUADO AG, 1979. Prinzmetals's
angina: reflex cardiovascular response during episode of pain. British
Medical Journal 42:81-87.
PERNEY TM, MILLER RJ, 1989. Two different G-proteins mediate neuropeptide Y
and bradykinin- stimulated phospholipid breakdown in cultured rat sensory
neurons. Journal of Biological Chemistry 264:7317-7327.
PERNOW J, LUNDBERG JM, KAIJSER L, HJEMDAHL P, THEODORSSONNORHEIM
E, MARTINSSON A, PERNOW B, 1986. Plasma neuropeptide
221
Y-like immunoreactivity and catecholamines during various degrees of
sympathethic activation in man. Clinical Physiology 6:561-578.
PERNOW J, SARIA A, LUNDBERG JM, 1986a. Mechanisms underlying pre- and
postjunctional effects of neuropeptide Y in sympathetic vascular control. Acta
Physiologica Scandinavica 126:239-249.
PERNOW J, SCHWIELER J, KAHAN T, HJEMDAHL P, OBERLE J, WALLIN
BG, LUNDBERG JM, 1989. Influence of sympathetic discharge pattern on
norepinephrine and neuropeptide Y release. American Journal of Physiology
257:Pt 2):H866-72.
PERNOW J, 1994. Co-release and functional interactions of neuropeptide Y and
noradrenaline in peripheral sympathetic vascular control. Acta Physiologica
Scandinavica Supplementum:1988;568:1-56.
PETITTO JM, HUANG Z, MCCARTHY DB, 1994. Molecular cloning of NPY-Y1
receptor cDNA from rat splenic lymphocytes: evidence of low levels of
mRNA expression and [125I]NPY binding sites. Journal of
Neuroimmunology 54:81-86.
PETRETTA M, BONADUCE D, SCALFI L, DE FILIPPO E, MARCIANO F,
MIGAUX ML, THEMISTOCLAKIS S, IANNICIELLO A, CONTALDO F,
1997. Heart rate variability as a measure of autonomic nervous system
function in anorexia nervosa. Clinical Cardiology 20:219-224.
222
PIROLA FT, POTTER EK, 1990. Vagal action on atrioventricular conduction and its
inhibition by sympathetic stimulation and neuropeptide Y in anaesthetised
dogs. Journal of the Autonomic Nervous System 31:1-12.
PLAYFORD RJ, COX HM, 1996. Peptide YY and neuropeptide Y: two peptides
intimately involved in electrolyte homeostasis. [Review] Trends in
Pharmacological Sciences 17:436-438.
PLECHA DM, RANDALL WC, GEIS GS, WURSTER RD, 1988. Localization of
vagal preganglionic somata controlling sinoatrial and atrioventricular nodes.
American Journal of Physiology 255:R703-R708.
POTTER EK, MCCLOSKEY DI, 1983. Peripheral inhibition of cardiac vagal action
by sympathetic adrenergic stimulation. Proceedings of the Society for
Experimental Pharmacology & Physiology 10:661.
POTTER EK, 1984. Prolonged non-adrenergic inhibition of cardiac vagal action by
sympathetic stimulation: a role for neuropeptide Y? Proceedings of the
Australian Physiological and Pharmacological Society 15:200P.
POTTER EK, 1985. Prolonged non-adrenergic inhibition of cardiac vagal action
following sympathetic stimulation: neuromodulation by neuropeptide Y?
Neuroscience Letters. 54:117-121.
POTTER EK, PARKER P, CAINE AC, LUMBERS ER, 1985a. Potentiation of
cardiac vagal action by cold. Clinical Science 68:165-169.
223
POTTER EK, MCCLOSKEY DI, 1986. Effects of hypoxia on cardiac vagal efferent
activity and on the action of the vagus nerve at the heart in the dog. Journal
of the Autonomic Nervous System 17:325-329.
POTTER EK, 1987. Cardiac vagal action and plasma levels of neuropeptide Y
following intravenous injection in the dog. Neuroscience Letters 77:243-247.
POTTER EK, 1987a. Guanethidine blocks neuropeptide-Y-like inhibitory action of
sympathetic nerves on cardiac vagus. Journal of the Autonomic Nervous
System 21:87-90.
POTTER EK, 1987b. Presynaptic inhibition of cardiac vagal postganglionic nerves
by neuropeptide Y. Neuroscience Letters. 83:101-106.
POTTER EK, 1988. Neuropeptide Y as an autonomic neurotransmitter. [Review].
Pharmacology & Therapeutics 37:251-273.
POTTER EK, MITCHELL L, MCCLOSKEY MJ, TSENG A, GOODMAN AE,
SHINE J, MCCLOSKEY DI, 1989. Pre- and postjunctional actions of
neuropeptide Y and related peptides. Regulatory Peptides 25:167-177.
POTTER EK, FUHLENDORFF J, SCHWARTZ TW, 1991. [Pro34]neuropeptide Y
selectively identifies postjunctional- mediated actions of neuropeptide Y in
vivo in rats and dogs. European Journal of Pharmacology 193:15-19.
POTTER EK, MCCLOSKEY DI, 1991a. Peptide YY reduces effects of sympathetic
nerves and neuropeptide Y on cardiac vagal action. Peptides 12:805-808.
224
POTTER EK, EDVINNSSON L, GUSTAFSSON T, 1992. Antagonism of pre- and
postjunctional responses to neuropeptide Y by D-myo-inositol-1,2,6-
triphosphate in the anaesthetised dog. European Journal of Pharmacology
221:307-314.
POTTER EK, PERSICO M, MITCHELL L, DE PIETRA MG, LOUGHNAN M,
SHINE J, MCCLOSKEY DI, 1992a. Dependence of hypotensive effect of
neuropeptide-Y 18-36 fragment on intact vagus nerves. Journal of the
Autonomic Nervous System 37:155-162.
POTTER EK, BARDEN JA, MCCLOSKEY MJ, SELBIE LA, TSENG A, HERZOG
H, SHINE J, 1994. A novel neuropeptide Y analog, N-acetyl [Leu28,
Leu31]neuropeptide Y-(24-36), with functional specificity for the presynaptic
(Y2) receptor. European Journal of Pharmacology 267:253-262.
PYNER S, COOTE JH, 1994. A comparison between the adult rat and neonate rat of
the architecture of sympathetic preganglionic neurones projecting to the
superior cervical ganglion, stellate ganglion and adrenal medulla. Journal of
the Autonomic Nervous System . 48:153-166.
RANDALL WC, ARDELL JL, WURSTER RD, MILOSAVLJEVIC M, 1987. Vagal
postganglionic innervation of the canine sinoatrial node. Journal of the
Autonomic Nervous System 20:13-23.
REN LM, FURUKAWA Y, KARASAWA Y, MURAKAMI M, TAKEI M,
NARITA M, CHIBA S, 1991. Differential inhibition of neuropeptide Y on
the chronotropic and inotropic responses to sympathetic and parasympathetic
225
stimulation in the isolated, perfused dog atrium. Journal of Pharmacology
and Experimental Therapeutics 259:38-43.
REVINGTON M, POTTER EK, MCCLOSKEY DI, 1990. Prolonged inhibition of
cardiac vagal action following sympathetic stimulation and galanin in
anaesthetized cats. Journal of Physiology 431:495-503.:495-503.
RIOUX F, BACHELARD H, MARTEL JC, ST-PIERRE S, 1986. The
vasoconstrictor effect of neuropeptide Y and related peptides in the guinea
pig isolated heart. Peptides 7:27-31.
RIST B, ZERBE O, INGENHOVEN N, SCAPOZZA L, PEERS C, VAUGHAN PF,
MCDONALD RL, WIELAND HA, BECK-SICKINGER AG, 1996.
Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full
agonist at the human Y2 receptor. FEBS Letters 394:169-173.
ROSE PM, FERNANDES P, LYNCH JS, FRAZIER ST, FISHER SM,
KODUKULA K, KIENZLE B, SEETHALA R, 1995. Cloning and functional
expression of a cDNA encoding a human type 2 neuropeptide Y receptor.
Journal of Biological Chemistry 270:22661-22664.
ROSE PM, LYNCH JS, FRAZIER ST, FISHER SM, CHUNG W, BATTAGLINO
P, FATHI, LEIBEL R, FERNANDES P, 1997. Molecular genetic analysis of
a human neuropeptide Y receptor. The human homolog of the murine "Y5"
receptor may be a pseudogene. Journal of Biological Chemistry 272:3622-
3627.
226
ROTHEMUND S, KRAUSE E, BEYERMANN M, BIENERT M, SYKES BD,
SONNICHSEN FD, 1996. Assignment of the helical structure in
neuropeptide Y by HPLC studies of methionine replacement analogues and
1H-NMR spectroscopy. Biopolymers 39:207-219.
RUDEHILL A, SOLLEVI A, FRANCO-CERECEDA A, LUNDBERG JM, 1986.
Neuropeptide Y (NPY) and the pig heart: release and coronary
vasoconstrictor effects. Peptides 7:821-826.
RUDEHILL A, OLCEN M, SOLLEVI A, HAMBERGER B, LUNDBERG JM,
1987. Release of neuropeptide Y upon haemorrhagic hypovolaemia in
relation to vasoconstrictor effects in the pig. Acta Physiologica Scandinavica
131:517-523.
RUDOLF K, EBERLEIN W, ENGEL W, WIELAND HA, WILLIM KD,
ENTZEROTH M, WIENEN W, BECK-SICKINGER AG, DOODS HN,
1994. The first highly potent and selective non-peptide neuropeptide Y Y1
receptor antagonist: BIBP3226. European Journal of Pharmacology
271:R11-3.
RUMP LC, 1995. a2-adrenoceptor-modulated release of noradrenaline in human
right atrium. British Journal of Pharmacology 116:2617-2624.
SAINSBURY A, SCHWARZER C, COUZENS M, FETISSOV S, FURTINGER S,
JENKINS A, COX HM, SPERK G, HOKFELT T, HERZOG H, 2002.
Important role of hypothalamic Y2 receptors in body weight regulation
revealed in conditional knockout mice. Proceedings of the National Academy
of Science U. S. A. 99:8938-8943.
227
SAINSBURY A, SCHWARZER C, COUZENS M, HERZOG H, 2002a. Y2 receptor
deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes
51:3420-3427.
SAINSBURY A, SCHWARZER C, COUZENS M, JENKINS A, OAKS SR,
ORMANDY CJ, HERZOG H, 2002b. Y4 receptor knockout rescues fertility
in ob/ob mice. Genes and Development 16:1077-1088.
SAMAAN A, 1935. The antagonistic cardiac nerves and heart rate. Journal of
Physiology-London 83:332-340.
SAUDEK V, PELTON JT, 1990. Sequence-specific 1H NMR assignment and
secondary structure of neuropeptide Y in aqueous solution. Biochemistry
29:4509-4515.
SCHOBER DA, VAN ABBEMA AM, SMILEY DL, BRUNS RF, GEHLERT, DR,
1998. The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the
human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides
19:537-542.
SCHWARTZ PJ, PAGANI M, LOMBARDI F, MALLANI A, BROWN AM, 1973.
A cardiogenic sympathovagal reflex in the cat. Circulation Research 32:215-
220.
SCHWARTZ TW, 1983. Pancreatic polypeptide: a unique model for vagal control of
endocrine systems. Journal of the Autonomic Nervous System 9:99-111.
SCHWARTZ TW, FUHLENDORFF J, LANGELAND N, THORGERSEN H,
JORGENSEN FC, SHEIKH S, 1989. Y1 and Y2 receptors for NPY - the
228
evolution of PP-fold peptides and their receptors.In: Mutt V, Hokfelt T,
Lundberg JM, eds. Neuropeptide Y. New York: Raven Press, 143-151.
SELLER H, ILLERT M, 1969. The localization of the first synapse in the carotid
sinus baroreceptor reflex pathway and its alteration of the afferent input.
Pflugers Archiv - European Journal of Physiology 306:1-19.
SERONE AP, ANGUS JA, 1999. Neuropeptide Y is a prejunctional inhibitor of
vagal but not sympathetic inotropic responses in guinea-pig isolated left atria.
British Journal of Pharmacology 27:383-390.
SERONE AP, WRIGHT CE, ANGUS JA, 1999a. Heterogeneity of prejunctional
NPY receptor-mediated inhibition of cardiac neurotransmission. British
Journal of Pharmacology 127:99-108.
SERRADEIL-LE GC, VALETTE G, ROUBY PE, PELLET A, OURY-DONAT F,
BROSSARD G, LESPY L, MARTY E, NELIAT G, DE COINTET P, 1995.
SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor
antagonist. FEBS Letters 362:192-196.
SHARMA P, HOLMBERG SK, ERIKSSON H, BECK-SICKINGER AG,
GRUNDEMAR L, LARHAMMAR D, 1998. Cloning and functional
expression of the guinea pig neuropeptide Y Y2 receptor. Regulatory
Peptides 75-76:23-28.
SHEIKH SP, ROACH E, FUHLENDORFF J, WILLIAMS JA, 1991. Localization of
Y1 receptors for NPY and PYY on vascular smooth muscle cells in rat
pancreas. American Journal of Physiology 260:Pt 1):G250-7.
229
SHERIFF S, RIGEL DF, FISCHER JE, BALASUBRAMANIAM A, 1990.
Interaction of 125I-neuropeptide Y with rat cardiac membranes.
Neuropeptides 15:157-160.
SINGH G, KAUR S, STOCK JL, JENKINS NA, GILBERT DJ, COPELAND NG,
POTTER SS, 1991. Identification of 10 murine homeobox genes.
Proceedings of the National Academy of Science U. S. A. 88:10706-10710.
SLEIGHT P, FOX P, LOPEZ R, BROOKS DE, 1978. The effect of mental
arithmetic on blood pressure variability and baroreflex sensitivity in man.
Clinical Science 55:381-382.
SLEIGHT P, FLORAS JS, HASSAN MO, JONES JV, OSIKOWSKA BA, SEVER
P, TURNER KL, 1979. Baroreflex control of blood pressure and plasma
noradrenaline during exercise in essential hypertension. Clinical Science
57:169-171.
SMITH-WHITE MA, MORIARTY MJ, POTTER EK, 1998. A comparison of
actions of neuropeptide Y (NPY) agonists and antagonists at NPY Y1 and Y2
receptors in anaesthetized rats. Neuropeptides 32:109-118.
SMITH-WHITE MA, WALLACE D, POTTER EK, 1999. Sympatheticparasympathetic
interactions at the heart in the anaesthetised rat. Journal of
the Autonomic Nervous System 75:171-175.
SMITH-WHITE MA, HARDY TA, BROCK JA, POTTER EK, 2001. Effects of a
selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors
230
at peripheral neuroeffector junctions. British Journal of Pharmacology
132:861-868.
SMITH-WHITE, M. A., HERZOG, H., POTTER, E K. 2002 Role of neuropeptide Y
receptors in modulation of cardiac parasympathetic neurotransmission.
Regulatory Peptides .103:105-111
STARBACK P, WRAITH A, ERIKSSON H, LARHAMMAR D, 2000.
Neuropeptide Y receptor gene y6: multiple deaths or resurrections?
Biochemical and Biophysical Research Communications 277:264-269.
STJERNQUIST M, EMSON P, OWMAN C, SJOBERG NO, SUNDLER F,
TATEMOTO K, 1983. Neuropeptide Y in the female reproductive tract of the
rat. Neuroscience Letters 39:279-284.
STRÖMBLAD BCR, NICKERSON M, 1961. Accumulation of epinephrine and
norepinephrine by some rat tissues. Journal of Pharmacology and
Experimental Therapeutics. 134:154-159.
SUN XY, DAHLOF C, EDVINSSON L, HEDNER T, 1991. D-myo-inositol-1,2,6-
trisphosphate is a selective antagonist of neuropeptide Y-induced pressor
responses in the pithed rat. European Journal of Pharmacology 204:281-
286.
TATEMOTO K, MANN MJ, SHIMIZU M, 1992. Synthesis of receptor antagonists
of neuropeptide Y. Proceedings of the National Academy of Science U. S. A.
89:1174-1178.
231
TAVERNIER G, DAMASE-MICHEL C, TRAN MA, MONTASTRUC JL,
MONTASTRUC P, 1992. [Differential regulation of the release of
norepinephrine and neuropeptide Y]. [French]. Archives des Maladies du
Coeur et des Vaisseaux 85:1137-1140.
TAYLOR EW, 1994. The evolution of efferent vagal control of the heart in
vertebrates. Cardioscience 5:173-182.
THAMES MD, KONTOS HA, 1970. Mechanisms of baroreceptor induced changes
in heart rate. American Journal of Physiology 218:251-256.
TODA N, SHIMAMOTO K, 1968. The influence of sympathetic stimulation on
transmembranepotentialsin the S-A node. Journal of Pharmacology and
Experimental Therapeutics 159:298-305.
TOTH PT, BINDOKAS VP, BLEAKMAN D, COLMERS WF, MILLER RJ, 1993.
Mechanism of presynaptic inhibition by neuropeptide Y at sympathetic nerve
terminals. Nature 364:635-639.
TRINH T, VAN DUMONT Y, QUIRION R, 1996. High levels of specific
neuropeptide Y/pancreatic polypeptide receptors in the rat hypothalamus and
brainstem. European Journal of Pharmacology 318:R1-R3.
TRIVEDI PG, YU H, TRUMBAUER M, CHEN H, VAN DER PLOEG LH, GUAN
X, 2001. Differential regulation of neuropeptide Y receptors in the brains of
NPY knock-out mice. Peptides 22:395-403.
TRUEX RC, CARPENTER MB, 1969. Human Neuroanatomy.Baltimore MD:
Williams and Wilkins.
232
UDDMAN R, MOLLER S, NILSSON T, NYSTROM S, EKSTRAND J,
EDVINNSSON L, 2002. Neuropeptide Y Y1 and neuropeptide Y Y2
receptors in human cardiovascular tissues. Peptides 23:927-934.
UHE AM, SZMUKLER GI, COLLIER GR, HANSKY J, O'DEA K, YOUNG GP,
1992. Potential regulators of feeding behavior in anorexia nervosa. American
Journal of Clinical Nutrition 55:28-32.
ULLMAN B, FRANCO-CERECEDA A, HULTING J, LUNDBERG JM, SOLLEVI
A, 1990. Elevation of plasma neuropeptide Y-like immunoreactivity and
noradrenaline during myocardial ischaemia in man. Journal of Internal
Medicine 228:583-589.
ULMAN LG, POTTER EK, MCCLOSKEY DI, MORRIS MJ, 1997. Post-exercise
depression of baroreflex slowing of the heart in humans. Clinical Physiology
17:299-309.
VANCE WH, BOWKER RC, 1983. Spinal origins of cardiac afferents from the
region of the left anterior descending artery. Brain Research, Molecular
Brain Research 258:96-100.
WAHLESTEDT C, EDVINSSON L, EKBLAD E, HAKANSON R, 1985.
Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of
action. Journal of Pharmacology and Experimental Therapeutics 234:735-
741.
233
WAHLESTEDT C, HAKANSON R, 1986. Effects of neuropeptide Y (NPY) at the
sympathetic neuroeffector junction. Can pre- and postjunctional receptors be
distinguished? Medical Biology 64:85-88.
WAHLESTEDT C, YANAIHARA N, HAKANSON R, 1986a. Evidence for
different pre-and post-junctional receptors for neuropeptide Y and related
peptides. Regulatory Peptides 13:307-318.
WAHLESTEDT C, REGUNATHAN S, REIS DJ, 1992. Identification of cultured
cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide
Y/peptide YY. Life Sciences 50:PL7-12.
WAHLESTEDT C, PICH EM, KOOB GF, YEE F, HEILIG M, 1993. Modulation of
anxiety and neuropeptide Y-Y1 receptors by antisense
oligodeoxynucleotides. Science 259:528-531.
WALKER MW, EWALD DA, PERNEY TM, MILLER RJ, 1988. Neuropeptide Y
modulates neurotransmitter release and Ca2+ currents in rat sensory neurons.
Journal of Neuroscience 8:2438-2446.
WALKER MW, SMITH KE, BARD J, VAYSSE PJJ, GERALD C, DAOUTI S,
WEINSHANK RL, BRANCHEK TA, 1997.